Skip to main content

Zegerid OTC Side Effects

Generic name: omeprazole / sodium bicarbonate

Medically reviewed by Drugs.com. Last updated on Mar 28, 2023.

Note: This document contains side effect information about omeprazole / sodium bicarbonate. Some dosage forms listed on this page may not apply to the brand name Zegerid OTC.

Applies to omeprazole / sodium bicarbonate: oral capsule, oral packet, oral powder for suspension.

Serious side effects of Zegerid OTC

Along with its needed effects, omeprazole/sodium bicarbonate may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking omeprazole / sodium bicarbonate:

More common

Less common

Rare

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking omeprazole / sodium bicarbonate:

Symptoms of overdose

Other side effects of Zegerid OTC

Some side effects of omeprazole / sodium bicarbonate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to omeprazole / sodium bicarbonate: oral capsule, oral powder for reconstitution, oral suspension.

Other

Very common (10% or more): Pyrexia (Up to 20.2%)

Common (1% to 10%): Hyperpyrexia

Omeprazole:

Common (1% to 10%): Asthenia

Postmarketing reports: Fatigue, fever, malaise, pain, tinnitus[Ref]

Metabolic

Very common (10% or more): Hypokalemia (Up to 12.4%), hyperglycemia NOS (Up to 10.7%), hypomagnesemia (Up to 10.1%)

Common (1% to 10%): Fluid overload, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia NOS, hyponatremia, hypophosphatemia

Frequency not reported: Cyanocobalamin (vitamin B-12) deficiency

Omeprazole:

Postmarketing reports: Anorexia, hypoglycemia, hypomagnesemia, hyponatremia, weight gain

Sodium Bicarbonate:

Postmarketing reports: Metabolic acidosis, tetany[Ref]

Respiratory

Very common (10% or more): Nosocomial pneumonia (Up to 11.2%)

Common (1% to 10%): Acute respiratory distress syndrome, respiratory failure

Uncommon (0.1% to 1%): Pneumothorax NOS

Omeprazole:

Common (1% to 10%): Cough, upper respiratory infection

Postmarketing reports: Bronchospasm, epistaxis, pharyngeal pain[Ref]

Hematologic

Very common (10% or more): Thrombocytopenia (Up to 10.1%)

Common (1% to 10%): Anemia NOS, anemia NOS aggravated

Omeprazole:

Postmarketing reports: Agranulocytosis/fatal agranulocytosis, anemia, hemolytic anemia, leukocytosis, leukopenia, neutropenia, pancytopenia, thrombocytopenia[Ref]

Cardiovascular

Common (1% to 10%): Atrial fibrillation, bradycardia not otherwise specified (NOS), edema NOS, hypertension NOS, hypotension NOS, supraventricular tachycardia, tachycardia NOS, ventricular tachycardia

Omeprazole:

Postmarketing reports: Bradycardia, chest pain/angina, elevated blood pressure, palpitation, peripheral edema, tachycardia[Ref]

Gastrointestinal

Common (1% to 10%): Constipation, diarrhea NOS, gastric hypomobility, oral candidiasis

Frequency not reported: Clostridium difficile-associated diarrhea, fundic gland polyps, upper gastrointestinal bleeding

Omeprazole:

Common (1% to 10%): Abdominal pain, acid regurgitation, constipation, diarrhea, flatulence, nausea, vomiting

Postmarketing reports: Abdominal swelling, Clostridium difficile associated diarrhea, dry mouth, esophageal candidiasis, fecal discoloration, gastric fundic gland polyps, irritable colon, mucosal atrophy of the tongue, pancreatitis/fatal pancreatitis, stomatitis[Ref]

Benign gastric fundic gland polyps occurred rarely and appeared to be reversible when omeprazole was discontinued.[Ref]

Dermatologic

Common (1% to 10%): Decubitus ulcer, rash NOS

Frequency not reported: Cutaneous lupus erythematosus, systemic lupus erythematosus

Omeprazole:

Common (1% to 10%): Rash

Postmarketing reports: Alopecia, cutaneous lupus erythematosus, dry skin, erythema multiforme/severe erythema multiforme, hyperhidrosis, photosensitivity, pruritus, purpura and/or petechia with/without rechallenge, severe generalized skin reactions, skin inflammation, Stevens-Johnson syndrome, systemic lupus erythematosus, toxic epidermal necrolysis (TEN)/fatal TEN, urticaria[Ref]

Hepatic

Common (1% to 10%): Abnormal liver function tests NOS

Omeprazole:

Postmarketing reports: Hepatocellular/cholestatic/mixed hepatitis, jaundice, liver failure/fatal liver failure, liver necrosis/fatal liver necrosis, mild to marked elevation of liver function tests (alkaline phosphatase, ALT, AST, gamma-glutamyl transpeptidase), overt liver disease[Ref]

Immunologic

Common (1% to 10%): Candidal infection NOS, sepsis NOS[Ref]

Psychiatric

Common (1% to 10%): Agitation

Omeprazole:

Postmarketing reports: Abnormal dreams, aggression, agitation, anxiety, apathy, confusion, depression, hallucinations, insomnia, nervousness, psychiatric disturbances[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection, urinary tract infection NOS

Omeprazole:

Postmarketing reports: Hematuria, microscopic pyuria, proteinuria, testicular pain, urinary frequency, urinary tract infection[Ref]

Nervous system

Omeprazole:

Common (1% to 10%): Headache, dizziness

Postmarketing reports: Hemifacial dysesthesia, hepatic encephalopathy, paresthesia, somnolence, taste perversion, tremors, vertigo

Sodium Bicarbonate:

Postmarketing reports: Seizures[Ref]

Musculoskeletal

Frequency not reported: Bone fracture

Omeprazole:

Common (1% to 10%): Back pain

Postmarketing reports: Bone fracture, joint pain, leg pain, muscle cramps, muscle weakness, myalgia[Ref]

Ocular

Omeprazole:

Postmarketing reports: Anterior ischemic optic neuropathy, blurred vision, double vision, dry eye syndrome, ocular irritation, optic atrophy, optic neuritis[Ref]

Hypersensitivity

Omeprazole:

Postmarketing reports: Anaphylactic shock, anaphylaxis, angioedema, hypersensitivity reactions[Ref]

Renal

Frequency not reported: Acute interstitial nephritis

Omeprazole:

Postmarketing reports: Elevated serum creatinine, glycosuria, interstitial nephritis with/without positive rechallenge[Ref]

Oncologic

Gastroduodenal carcinoids have been reported in patients with Zollinger-Ellison syndrome on long-term therapy. This condition may be a manifestation of the underlying condition, which is known to be associated with these tumors.[Ref]

Omeprazole:

Postmarketing reports: Gastroduodenal carcinoids[Ref]

Endocrine

Omeprazole:

Postmarketing reports: Gynecomastia[Ref]

More about Zegerid OTC (omeprazole / sodium bicarbonate)

Patient resources

Other brands

Konvomep

Professional resources

Other brands

Konvomep

Other formulations

Related treatment guides

References

1. Product Information. Zegerid (omeprazole). Santarus Inc. 2004.

2. Product Information. Zegerid (omeprazole-sodium bicarbonate). Santarus Inc. 2006.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.